This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
The joint initiative is called J-ARC Healthcare Solutions
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
The Genome Valley region has played a pivotal role in fostering the life science industry and the state government has always supported its growth
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
Alchemee's flagship brand Proactiv@ is an iconic product synonymous with acne care
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
The facility will manufacture its Herceptin biosimilar, Tuznue
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Subscribe To Our Newsletter & Stay Updated
